Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Fed's Musalem: It Is Too Early to Decide on September Rate Decision

Fed's Musalem: It Is Too Early to Decide on September Rate Decision

ChaincatcherChaincatcher2025/08/14 16:07
Show original

According to ChainCatcher, citing Jinshi Data, Federal Reserve official Musalem stated that it is still too early to decide whether to cut interest rates at next month's meeting. When asked if there was any reason to cut rates by 50 basis points next month, Musalem said that from his perspective, this would "not be supported by the current economic conditions and outlook."

Musalem noted that on one hand, "the data is starting to give us some indications as to whether there is a possibility of persistent inflation." At the same time, he mentioned "downside risks in the labor market."

Musalem stated that the slowdown in U.S. economic growth, combined with the pressure tariffs are putting on corporate profit margins, could threaten the labor market, which has performed well so far. He said, "I am weighing these two factors, and when we see tension between our two objectives, we need to adopt a balanced approach."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56